[1]
Andreesen, R.; Modolell, M.; Weltzien, H.U.; Eibl, H.; Common, H.H.; Lohr, G.W.; Munder, P.G. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res., 1978, 38(11 Pt 1), 3894-3899.
[2]
Berdel, W.E.; Bausert, W.R.; Weltzien, H.U.; Modolell, M.L.; Widmann, K.H.; Munder, P.G. The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur. J. Cancer, 1980, 16(9), 1199-1204.
[3]
Berger, M.R.; Munder, P.G.; Schmahl, D.; Westphal, O. Influence of the alkyllysophospholipid ET-18-OCH3 on methylnitrosourea-induced rat mammary carcinomas. Oncology, 1984, 41(2), 109-113.
[4]
Grunicke, H.; Hofmann, J. Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. Pharmacol. Ther., 1992, 55(1), 1-30.
[5]
Berdel, W.E.; Fink, U.; Rastetter, J. Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3. Lipids, 1987, 22(11), 967-969.
[6]
Berger, M.R.; Schmahl, D. Modulation of chemical carcinogenesis in rats by alkyl lysophospholipids. Lipids, 1987, 22(11), 935-942.
[7]
Woolley, P.V.; Schultz, C.J.; Rodriguez, G.I.; Gams, R.A.; Rowe, K.W., Jr; Dadey, M.L.; Von Hoff, D.D.; McPhillips, J.J. A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma. Invest. New Drugs, 1996, 14(2), 219-222.
[8]
Herrmann, D.B.; Opitz, H.G.; Munder, P.G. Antitumor activity of Ilmofosine (BM 41.440) in the 3Lewis-lung carcinoma model. Lipids, 1991, 26(12), 1431-1436.
[9]
Berger, M.R.; Muschiol, C.; Eibl, H.J. New cytostatics with experimentally different toxic profiles. cancer Treat. Rev., 1987, 14, 307-317.
[10]
Breiser, A.; Kim, D.J.; Fleer, E.A.; Damenz, W.; Drube, A.; Berger, M.; Nagel, G.A.; Eibl, H.; Unger, C. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids, 1987, 22(11), 925-926.
[11]
Verweij, J.; Planting, A.; van der Burg, M.; Stoter, G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J. Cancer Res. Clin. Oncol., 1992, 118(8), 606-608.
[12]
Zeisig, R.; Jungmann, S.; Arndt, D.; Schutt, A.; Nissen, E. Antineoplastic activity in vitro of free and liposomal alkylphosphocholines. Anticancer Drugs, 1993, 4(1), 57-64.
[13]
Unger, C.; Berdel, W.; Hanauske, A.R.; Sindermann, H.; Engel, J.; Mross, K. First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur. J. Cancer, 2010, 46(5), 920-925.
[14]
Bendell, J.C.; Nemunaitis, J.; Vukelja, S.J.; Hagenstad, C.; Campos, L.T.; Hermann, R.C.; Sportelli, P.; Gardner, L.; Richards, D.A. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J. Clin. Oncol., 2011, 29(33), 4394-4400.
[15]
Konigs, S.K.; Pallasch, C.P.; Lindner, L.H.; Schwamb, J.; Schulz, A.; Brinker, R.; Claasen, J.; Veldurthy, A.; Eibl, H.; Hallek, M.; Wendtner, C.M. Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway. Leuk. Res., 2010, 34(8), 1064-1069.
[16]
Kapoor, V.; Zaharieva, M.M.; Das, S.N.; Berger, M.R. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma. Cancer Lett., 2012, 319(1), 39-48.
[17]
Fiegl, M.; Lindner, L.H.; Juergens, M.; Eibl, H.; Hiddemann, W.; Braess, J. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother. Pharmacol., 2008, 62(2), 321-329.
[18]
Martelli, A.M.; Papa, V.; Tazzari, P.L.; Ricci, F.; Evangelisti, C.; Chiarini, F.; Grimaldi, C.; Cappellini, A.; Martinelli, G.; Ottaviani, E.; Pagliaro, P.; Horn, S.; Basecke, J.; Lindner, L.H.; Eibl, H.; McCubrey, J.A. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia, 2010, 24(4), 687-698.
[19]
Henke, G.; Lindner, L.H.; Vogeser, M.; Eibl, H.J.; Worner, J.; Muller, A.C.; Bamberg, M.; Wachholz, K.; Belka, C.; Jendrossek, V. Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy. Radiat. Oncol., 2009, 4, 46.
[20]
Clark, P.A.; Al-Ahmad, A.J.; Qian, T.; Zhang, R.R.; Wilson, H.K.; Weichert, J.P.; Palecek, S.P.; Kuo, J.S.; Shusta, E.V. Analysis of cancer-targeting alkylphosphocholine analogue permeability characteristics using a human induced pluripotent stem cell blood-brain barrier model. Mol. Pharm., 2016, 13(9), 3341-3349.
[21]
Pinchuk, A.N.; Rampy, M.A.; Longino, M.A.; Skinner, R.W.; Gross, M.D.; Weichert, J.P.; Counsell, R.E. Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues. J. Med. Chem., 2006, 49(7), 2155-3265.
[22]
Weichert, J.P.; Clark, P.A.; Kandela, I.K.; Vaccaro, A.M.; Clarke, W.; Longino, M.A.; Pinchuk, A.N.; Farhoud, M.; Swanson, K.I.; Floberg, J.M.; Grudzinski, J.; Titz, B.; Traynor, A.M.; Chen, H.E.; Hall, L.T.; Pazoles, C.J.; Pickhardt, P.J.; Kuo, J.S. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci. Transl. Med., 2014, 6(240), 240ra75.
[23]
Swanson, K.I.; Clark, P.A.; Zhang, R.R.; Kandela, I.K.; Farhoud, M.; Weichert, J.P.; Kuo, J.S. Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection. Neurosurgery, 2015, 76(2), 115-123.
[24]
Garland, M.; Yim, J.J.; Bogyo, M. A bright future for precision medicine: advances in fluorescent chemical probe design and their clinical application. Cell Chem. Biol., 2016, 23(1), 122-136.
[25]
Korb, M.L.; Warram, J.M.; Grudzinski, J.; Weichert, J.; Jeffery, J.; Rosenthal, E.L. Breast cancer imaging using the near-infrared fluorescent agent, CLR1502. Mol. Imaging, 2014, 13.
[26]
Zhang, R.R.; Schroeder, A.B.; Grudzinski, J.J.; Rosenthal, E.L.; Warram, J.M.; Pinchuk, A.N.; Eliceiri, K.W.; Kuo, J.S.; Weichert, J.P. Beyond the margins: real-time detection of cancer using targeted fluorophores. Nat. Rev. Clin. Oncol., 2017, 14(6), 347-364.
[27]
Zhang, R.R.; Swanson, K.I.; Hall, L.T.; Weichert, J.P.; Kuo, J.S. Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies. CNS Oncol., 2016, 5(4), 223-231.
[28]
Fleer, E.A.; Unger, C.; Kim, D.J.; Eibl, H. Metabolism of ether phospholipids and analogs in neoplastic cells. Lipids, 1987, 22(11), 856-861.
[29]
Eibl, H.; Unger, C. Phospholipide als antitumormittel: Moeglichkeiten
einer selektiven therapie. Die Zellmembran als angriffspunt
der tumortherapie. zuckerschwerdt: Muenchen. 1987, pp 1-18.
[30]
Berger, M.R.; Yanapirut, P.; Reinhardt, M.; Klenner, T.; Scherf, H.R.; Schmeiser, H.H.; Eibl, H. Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas. Prog. Exp. Tumor Res., 1992, 34, 98-115.
[31]
Konstantinov, S.M.; Topashka-Ancheva, M.; Benner, A.; Berger, M.R. Alkylphosphocholines: Effects on human leukemic cell lines and normal bone marrow cells. Int. J. Cancer, 1998, 77(5), 778-786.
[32]
Konstantinov, S.M.; Eibl, H.; Berger, M.R. BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. Br. J. Haematol., 1999, 107(2), 365-380.
[33]
Konstantinov, S.M.; Berger, M.R. Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines. Cancer Lett., 1999, 144(2), 153-160.
[34]
Konstantinov, S.M.; Eibl, H.; Berger, M.R. Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells. Cancer Chemother. Pharmacol., 1998, 41(3), 210-216.
[35]
Bagley, R.G.; Kurtzberg, L.; Rouleau, C.; Yao, M.; Teicher, B.A. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Cancer Chemother. Pharmacol., 2011, 68(6), 1537-1546.
[36]
Yosifov, D.Y.; Todorov, P.T.; Zaharieva, M.M.; Georgiev, K.D.; Pilicheva, B.A.; Konstantinov, S.M.; Berger, M.R. Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemother. Pharmacol., 2010, 67(1), 13-25.
[37]
Martinova, Y.; Topashka-Ancheva, M.; Konstantinov, S.; Petkova, S.; Karaivanova, M.; Berger, M. Miltefosine decreases the cytotoxic effect of Epirubicine and Cyclophosphamide on mouse spermatogenic, thymic and bone marrow cells. Arch. Toxicol., 2006, 80(1), 27-33.
[38]
Koetting, J.; Berger, M.R.; Unger, C.; Eibl, H. Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. Cancer Chemother. Pharmacol., 1992, 30(2), 105-112.
[39]
Sobottka, S.B.; Berger, M.R.; Eibl, H. Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo. Int. J. Cancer, 1993, 53(3), 418-425.
[40]
Papazafiri, P.; Avlonitis, N.; Angelou, P.; Calogeropoulou, T.; Koufaki, M.; Scoulica, E.; Fragiadaki, I. Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives. Cancer Chemother. Pharmacol., 2005, 56(3), 261-270.
[41]
Vink, S.R.; Schellens, J.H.; van Blitterswijk, W.J.; Verheij, M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest. New Drugs, 2005, 23(4), 279-286.
[42]
Hideshima, T.; Catley, L.; Yasui, H.; Ishitsuka, K.; Raje, N.; Mitsiades, C.; Podar, K.; Munshi, N.C.; Chauhan, D.; Richardson, P.G.; Anderson, K.C. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107(10), 4053-4062.
[43]
Pitter, K.L.; Galban, C.J.; Galban, S.; Tehrani, O.S.; Li, F.; Charles, N.; Bradbury, M.S.; Becher, O.J.; Chenevert, T.L.; Rehemtulla, A.; Ross, B.D.; Holland, E.C.; Hambardzumyan, D. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One, 2011, 6(1), e14545.
[44]
Celeghini, C.; Voltan, R.; Rimondi, E.; Gattei, V.; Zauli, G. Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines. Invest. New Drugs, 2010, 29(2), 392-395.
[45]
Voltan, R.; Celeghini, C.; Melloni, E.; Secchiero, P.; Zauli, G. Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity. Br. J. Haematol., 2009, 148(6), 957-961.
[46]
Elrod, H.A.; Lin, Y.D.; Yue, P.; Wang, X.; Lonial, S.; Khuri, F.R.; Sun, S.Y. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol. Cancer Ther., 2007, 6(7), 2029-2038.
[47]
Catley, L.; Hideshima, T.; Chauhan, D.; Neri, P.; Tassone, P.; Bronson, R.; Song, W.; Tai, Y.T.; Munshi, N.C.; Anderson, K.C. Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp. Hematol., 2007, 35(7), 1038-1046.
[48]
Nyakern, M.; Cappellini, A.; Mantovani, I.; Martelli, A.M. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol. Cancer Ther., 2006, 5(6), 1559-1570.
[49]
Jendrossek, V.; Hammersen, K.; Erdlenbruch, B.; Kugler, W.; Kruegener, R.; Eibl, H.; Lakomek, M. Structure-activity relationships of alkylphosphocholine derivates: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother. Pharmacol., 2002, 50, 71-79.
[50]
Thaler, A.; Hottkowitz, T.; Eibl, H. Separation and quantification of alkylphosphocholines by reversed phase high performance liquid chromatography. Chem. Phys. Lipids, 2000, 107(1), 131-139.
[51]
Grosman, N. Similar effects of ether phospholipids, PAF and lyso-PAF on the Ca(2+)-ATPase activity of rat brain synaptosomes and leukocyte membranes. Int. Immunopharmacol., 2001, 1(7), 1321-1329.
[52]
Eibl, H.; Kaufmann-Kolle, P. Medical application of synthetic phospholipids as liposomes and drugs. J. Liposome Res., 1995, 5, 131.
[53]
Kaufmann-Kolle, P.; Koetting, J.; Drevs, J.; Berger, M.; Unger, C.; Eibl, H. Intravenous application of alkylphosphocholines: Comparison of different homologues in lamellar structures. J. Cancer Res. Clin. Oncol., 1992, 120, R14.
[54]
Georgieva, M.C.; Konstantinov, S.M.; Topashka-Ancheva, M.; Berger, M.R. Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Lett., 2002, 182(2), 163-174.
[55]
Erdlenbruch, B.; Jendrossek, V.; Marx, M.; Hunold, A.; Eibl, H.; Lakomek, M. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo. Anticancer Res., 1998, 18(4A), 2551-2557.
[56]
Erdlenbruch, B.; Jendrossek, V.; Gerriets, A.; Vetterlein, F.; Eibl, H.; Lakomek, M. Erucylphosphocholine: Pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother. Pharmacol., 1999, 44(6), 484-490.
[57]
Jendrossek, V.; Erdlenbruch, B.; Hunold, A.; Kugler, W.; Eibl, H.; Lakomek, M. Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Int. J. Oncol., 1999, 14(1), 15-22.
[58]
Rubel, A.; Handrick, R.; Lindner, L.H.; Steiger, M.; Eibl, H.; Budach, W.; Belka, C.; Jendrossek, V. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat. Oncol., 2006, 1, 6.
[59]
Martelli, A.M.; Evangelisti, C.; Chiarini, F.; Grimaldi, C.; Manzoli, L.; McCubrey, J.A. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin. Investig. Drugs, 2009, 18(9), 1333-1349.
[60]
Yosifov, D.Y.; Konstantinov, S.M.; Berger, M.R.; Erucylphospho-N, N. N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells. Ann. N. Y. Acad. Sci., 2009, 1171, 350-358.
[61]
Zaharieva, M.M.; Konstantinov, S.M.; Pilicheva, B.; Karaivanova, M.; Berger, M.R. Erufosine: A membrane targeting antineoplastic agent with signal transduction modulating effects. Ann. N. Y. Acad. Sci., 2007, 1095, 182-192.
[62]
Henke, G.; Meier, V.; Lindner, L.H.; Eibl, H.; Bamberg, M.; Belka, C.; Budach, W.; Jendrossek, V. Effects of ionizing radiation in combination with Erufosine on T98G glioblastoma xenograft tumours: A study in NMRI nu/nu mice. Radiat. Oncol., 2012, 7, 172.
[63]
Dineva, I.K.; Zaharieva, M.M.; Konstantinov, S.M.; Eibl, H.; Berger, M.R. Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins. J. Cancer Res. Clin. Oncol., 2012, 138(11), 1909-1917.
[64]
Rudner, J.; Ruiner, C.E.; Handrick, R.; Eibl, H.J.; Belka, C.; Jendrossek, V. The Akt-inhibitor erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat. Oncol., 2010, 5, 108.
[65]
Zaharieva, M.M.; Kirilov, M.; Chai, M.; Berger, S.M.; Konstantinov, S.; Berger, M.R. Reduced expression of the retinoblastoma protein shows that the related signaling pathway is essential for mediating the antineoplastic activity of erufosine. PLoS One, 2014, 9(7), e100950.
[66]
Yosifov, D.Y.; Kaloyanov, K.A.; Guenova, M.L.; Prisadashka, K.; Balabanova, M.B.; Berger, M.R.; Konstantinov, S.M. Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines. Leuk. Res., 2014, 38(1), 49-56.
[67]
Kaleagasioglu, F.; Berger, M.R. Differential effects of erufosine on proliferation, wound healing and apoptosis in colorectal cancer cell lines. Oncol. Rep., 2014, 31(3), 1407-1416.
[68]
Chometon, G.; Cappuccini, F.; Raducanu, A.; Aumailley, M.; Jendrossek, V. The membrane-targeted alkylphosphocholine erufosine interferes with survival signals from the extracellular matrix. Anticancer. Agents Med. Chem., 2014, 14(4), 578-591.
[69]
Veenman, L.; Alten, J.; Linnemannstons, K.; Shandalov, Y.; Zeno, S.; Lakomek, M.; Gavish, M.; Kugler, W. Potential involvement of F0F1-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines: A mechanism for induction of apoptosis via the 18 kDa mitochondrial translocator protein. Apoptosis, 2010, 15(7), 753-768.
[70]
Berger, M.R.; Sobottka, S.B.; Konstantinov, S.; Eibl, H. Erucylphosphocholine is the prototype of i.v. injectable alkylphosphocholines. Drugs Today., 1998, 34, 73-81.
[71]
Fiegl, M.; Lindner, L.H.; Juergens, M.; Eibl, H.; Hiddemann, W.; Braess, J. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: Single activity and combination with other antileukemic drugs. Cancer Chemother. Pharmacol., 2008, 62(2), 321-329.
[72]
Baas, T. New route for old cancer agents. Science–Business eXChange, 2014, 7(27), 2.
[73]
Hilgard, P.; Klenner, T.; Stekar, J.; Unger, C. Alkylphosphocholines: A new class of membrane-active anticancer agents. Cancer Chemother. Pharmacol., 1993, 32(2), 90-95.
[74]
Ruiter, G.A.; Zerp, S.F.; Bartelink, H.; van Blitterswijk, W.J.; Verheij, M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res., 1999, 59(10), 2457-2463.
[75]
Rybczynska, M.; Spitaler, M.; Knebel, N.G.; Boeck, G.; Grunicke, H.; Hofmann, J. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol., 2001, 62(6), 765-772.
[76]
Naumann, U.; Wischhusen, J.; Weit, S.; Rieger, J.; Wolburg, H.; Massing, U.; Weller, M. Alkylphosphocholine-induced glioma cell death is BCL-X(L)-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation. Cell Death Differ., 2004, 11(12), 1326-1341.
[77]
Jendrossek, V.; Handrick, R. Membrane targeted anticancer drugs: Potent inducers of apoptosis and putative radiosensitisers. Curr. Med. Chem. Anticancer Agents, 2003, 3(5), 343-353.
[78]
Oberle, C.; Massing, U.; Krug, H.F. On the mechanism of alkylphosphocholine (APC)-induced apoptosis in tumour cells. Biol. Chem., 2005, 386(3), 237-245.
[79]
Gajate, C.; Mollinedo, F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood, 2007, 109(2), 711-719.
[80]
Gajate, C.; Mollinedo, F. The antitumor ether lipid ET-18-OCH (3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood, 2001, 98, 3860-3863.
[81]
Ward, P.D.; Ouyang, H.; Thakker, D.R. Role of phospholipase C-beta in the modulation of epithelial tight junction permeability. J. Pharmacol. Exp. Ther., 2003, 304(2), 689-698.
[82]
Lucas, L.; Hernandez-Alcoceba, R.; Penalva, V.; Lacal, J.C. Modulation of phospholipase D by hexadecylphosphorylcholine: A putative novel mechanism for its antitumoral activity. Oncogene, 2001, 20(9), 1110-1117.
[83]
Ruiter, G.A.; Zerp, S.F.; Bartelink, H.; van Blitterswijk, W.J.; Verheij, M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs, 2003, 14(2), 167-173.
[84]
Kumar, A.; Fillmore, H.L.; Kadian, R.; Broaddus, W.C.; Tye, G.W.; Van Meter, T.E. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma. Mol. Cancer Res., 2009, 7(11), 1813-1821.
[85]
Berger, M.; Tsoneva, I.; Konstantinov, S.; Eibl, H. Induction of apoptosis by Erucylphospho-N, N, N,-trimethylammonium is associated with changes in signal molecule expression and location. Ann. N. Y. Acad. Sci., 2003, 1010, 307-310.
[86]
Ruiter, G.A.; Verheij, M.; Zerp, S.F.; van Blitterswijk, W.J. Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys., 2001, 49(2), 415-419.
[87]
Cuvillier, O.; Janoff, E.M.; Liposomal, A.S. ET-18-OCH(3) induces cytochrom c-mediated apoptosis independently of CD95 (APO-1/Fas) signaling. Blood, 1999, 94, 3583-3592.
[88]
Ansari, S.S.; Sharma, A.K.; Soni, H.; Ali, D.M.; Tews, B.; Konig, R.; Eibl, H.; Berger, M.R. Induction of ER and mitochondrial stress by the alkylphosphocholine erufosine in oral squamous cell carcinoma cells. Cell Death Dis., 2018, 9(3), 296.
[89]
Matzke, A.; Massing, U.; Krug, H.F. Killing tumour cells by alkylphosphocholines: Evidence for involvement of CD95. Eur. J. Cell Biol., 2001, 80(1), 1-10.
[90]
Jendrossek, V.; Kugler, W.; Erdlenbruch, B.; Eibl, H.; Lakomek, M. Induction of differentiation and tetraploidy by long-term treatment of C6 rat glioma cells with erucylphosphocholine. Int. J. Oncol., 2001, 19(4), 673-680.
[91]
Jendrossek, V.; Mueller, I.; Eibl, H. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene, 2003, 22, 2621-2632.
[92]
Fu, L.; Kim, Y.A.; Wang, X.; Wu, X.; Yue, P.; Lonial, S.; Khuri, F.R.; Sun, S.Y. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res., 2009, 69(23), 8967-8976.
[93]
Jung, C.H.; Jun, C.B.; Ro, S-H.; Kim, Y-M.; Otto, N.M.; Cao, J.; Kundu, M.; Kim, D-H. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell, 2009, 20(7), 1992-2003.
[94]
Kapoor, V.; Zaharieva, M.M.; Berger, M.R. Erufosine Induces
Autophagy and Apoptosis in Oral Squamous Cell Carcinoma: Role
of the Akt-mTOR Signaling Pathway. In. Autophagy: Cancer,
Other Pathologies, Inflammation, Immunity, Infection, and Aging, 1st ed.; Hayat, M.A., Ed. Academic Press - Elsevier Inc.: Amsterdam,
2014, 3, pp 229-245
[95]
Xin, Y.; Shen, X.D.; Cheng, L.; Hong, D.F.; Chen, B. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. Cancer Chemother. Pharmacol., 2014, 73(4), 711-719.
[96]
Grosman, N. Influence of probes for calcium-calamodulin and protein kinase C signalling on the plasma membrane Ca2+-ATPase activity of rat synaptosomes and leukocyte membranes. Immunopharmacology, 1998, 40, 163-171.
[97]
Houlihan, W.J.; Lohmeyer, M.; Workman, P.; Cheon, S.H. Phospholipid antitumor agents. Med. Res. Rev., 1995, 15, 157-223.
[98]
Carafoli, E.; Stauffer, T. The plasma membrane calcium pump: Functional domains, regulation of the activity, and tissue specificity of isoform expression. J. Neurobiol., 1994, 25(3), 312-324.
[99]
van Blitterswijk, W.J.; Verheij, M. Anticancer mechanisms and clinical application of alkylphospholipids. Biochim. Biophys. Acta, 2013, 1831(3), 663-674.
[100]
van der Luit, A.H.; Budde, M.; Ruurs, P.; Verheij, M.; van Blitterswijk, W.J. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J. Biol. Chem., 2002, 277(42), 39541-39547.
[101]
Nieto-Miguel, T.; Gajate, C.; Mollinedo, F. Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells. J. Biol. Chem., 2006, 281(21), 14833-14840.
[102]
Van der Luit, A.H.; Budde, M.; Zerp, S.; Caan, W.; Klarenbeek, J.B.; Verheij, M.; Van Blitterswijk, W.J. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. Biochem. J., 2007, 401(2), 541-549.
[103]
van der Luit, A.H.; Vink, S.R.; Klarenbeek, J.B.; Perrissoud, D.; Solary, E.; Verheij, M.; van Blitterswijk, W.J. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol. Cancer Ther., 2007, 6(8), 2337-2345.
[104]
Vink, S.R.; van der Luit, A.H.; Klarenbeek, J.B.; Verheij, M.; van Blitterswijk, W.J. Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells. Biochem. Pharmacol., 2007, 74(10), 1456-1465.
[105]
Jaffrés, P-A.; Gajate, C.; Bouchet, A.M.; Couthon-Gourvés, H.; Chantome, A.; Potier-Cartereau, M.; Besson, P.; Bougnoux, P.; Mollinedo, F.; Vandier, C. Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy. Pharmacol. Ther., 2016, 165, 114-131.
[106]
Munoz-Martinez, F.; Torres, C.; Castanys, S.; Gamarro, F. CDC50A plays a key role in the uptake of the anticancer drug perifosine in human carcinoma cells. Biochem. Pharmacol., 2010, 80(6), 793-800.
[107]
Carrasco, M.P.; Jimenez-Lopez, J.M.; Rios-Marco, P.; Segovia, J.L.; Marco, C. Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues. Br. J. Pharmacol., 2010, 160(2), 355-366.
[108]
Jimenez-Lopez, J.M.; Rios-Marco, P.; Marco, C.; Segovia, J.L.; Carrasco, M.P. Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. Lipids Health Dis., 2010, 9, 33.
[109]
Pehlivanova, V.; Uzunova, V.; Tsoneva, I.; Berger, M.R.; Ugrinova, I.; Tzoneva, R. Effect of erufosine on the reorganization of cytoskeleton and cell death in adherent tumor and non-tumorigenic cells. Biotechnol. Biotechnol. Equip., 2014, 27(2), 3695-3699.
[110]
Follo, M.Y.; Manzoli, L.; Poli, A.; McCubrey, J.A.; Cocco, L. PLC and PI3K/Akt/mTOR signalling in disease and cancer. Adv. Biol. Regul., 2015, 57, 10-16.
[111]
Berkovic, D.; Goeckenjan, M.; Luders, S.; Hiddemann, W.; Fleer, E.A. Hexadecylphosphocholine inhibits phosphatidylinositol and phosphatidylcholine phospholipase C in human leukemia cells. J. Exp. Ther. Oncol., 1996, 1(5), 302-311.
[112]
Berkovic, D.; Berkovic, K.; Fleer, E.A.; Eibl, H.; Unger, C. Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines. Eur. J. Cancer, 1994, 30A(4), 509-515.
[113]
Uberall, F.; Oberhuber, H.; Maly, K.; Zaknun, J.; Demuth, L.; Grunicke, H.H. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res., 1991, 51(3), 807-812.
[114]
Maly, K.; Uberall, F.; Schubert, C.; Kindler, E.; Stekar, J.; Brachwitz, H.; Grunicke, H.H. Interference of new alkylphospholipid analogues with mitogenic signal transduction. Anticancer Drug Des., 1995, 10(5), 411-425.
[115]
Eibl, K.H.; Banas, B.; Kook, D.; Ohlmann, A.V.; Priglinger, S.; Kampik, A.; Welge-Luessen, U.C. Alkylphosphocholines: A new therapeutic option in glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci., 2004, 45(8), 2619-2624.
[116]
Eibl, K.H.; Kook, D.; Priglinger, S.; Haritoglou, C.; Yu, A.; Kampik, A.; Welge-Lussen, U. Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by alkylphosphocholines. Invest. Ophthalmol. Vis. Sci., 2006, 47(1), 364-370.
[117]
Ansari, S.S.; Akgun, N.; Berger, M.R. Erufosine increases RhoB expression in oral squamous carcinoma cells independent of its tumor suppressive mode of action - a short report. Cell Oncol. (Dordr.), 2017, 40(1), 89-96.
[118]
Pinton, G.; Manente, A.G.; Angeli, G.; Mutti, L.; Moro, L. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS One, 2012, 7(5), e36856.
[119]
Dasmahapatra, G.P.; Didolkar, P.; Alley, M.C.; Ghosh, S.; Sausville, E.A.; Roy, K.K. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin. Cancer Res., 2004, 10(15), 5242-5252.
[120]
Rahmani, M.; Reese, E.; Dai, Y.; Bauer, C.; Payne, S.G.; Dent, P.; Spiegel, S.; Grant, S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res., 2005, 65(6), 2422-2432.
[121]
Kondapaka, S.B.; Singh, S.S.; Dasmahapatra, G.P.; Sausville, E.A.; Roy, K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther., 2003, 2(11), 1093-1103.
[122]
Handrick, R.; Rubel, A.; Faltin, H.; Eibl, H.; Belka, C.; Jendrossek, V. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother. Oncol., 2006, 80(2), 199-206.
[123]
Li, X.; Luwor, R.; Lu, Y.; Liang, K.; Fan, Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene, 2006, 25(4), 525-535.
[124]
Gradziel, C.S.; Wang, Y.; Stec, B.; Redfield, A.G.; Roberts, M.F. Cytotoxic amphiphiles and phosphoinositides bind to two discrete sites on the Akt1 PH domain. Biochemistry, 2014, 53(3), 462-472.
[125]
Yosifov, D.Y.; Reufsteck, C.; Konstantinov, S.M.; Berger, M.R. Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines. Leuk. Res., 2012, 36(6), 764-772.
[126]
Hideshima, T.; Nakamur, N.; Chauhan, D.; Anderson, K.C. Biologic sequele of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 2001, 20, 5991-6000.
[127]
McCubrey, J.A.; Steelman, L.S.; Abrams, S.L.; Lee, J.T.; Chang, F.; Bertrand, F.E.; Navolanic, P.M.; Terrian, D.M.; Franklin, R.A.; D’Assoro, A.B.; Salisbury, J.L.; Mazzarino, M.C.; Stivala, F.; Libra, M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul., 2006, 46, 249-279.
[128]
van Blitterswijk, W.J.; Verheij, M. Anticancer alkylphospholipids: Mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr. Pharm. Des., 2008, 14(21), 2061-2074.
[129]
McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, E.W.; Chang, F.; Lehmann, B.; Terrian, D.M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A.M.; Franklin, R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta, 2007, 1773(8), 1263-1284.
[130]
Wada, T.; Penninger, J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 2004, 23(16), 2838-2849.
[131]
Lu, Z.; Xu, S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life, 2006, 58(11), 621-631.
[132]
Patel, V.; Lahusen, T.; Sy, T.; Sausville, E.A.; Gutkind, J.S.; Senderowicz, A.M. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res., 2002, 62(5), 1401-1409.
[133]
De Siervi, A.; Marinissen, M.; Diggs, J.; Wang, X.F.; Pages, G.; Senderowicz, A. Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: Role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1. Cancer Res., 2004, 64(2), 743-750.
[134]
Tomiyasu, H.; Goto-Koshino, Y.; Fujino, Y.; Ohno, K.; Tsujimoto, H. Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines. Vet. J., 2014, 201(1), 83-90.
[135]
Wang, F.Z.; Fei, H.R.; Li, X.Q.; Shi, R. Wang de, C. Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells. Mol. Cell. Biochem., 2012, 368(1-2), 1-8.
[136]
Zaharieva, M.M.; Amudov, G.; Konstantinov, S.M.; Guenova, M. Modern Therapy of Chronic Myeloid Leukemia.In Leukemia; Guenova, M.; Balatsenko, G., Eds.; InTech, 2013, pp. 227-244.
[137]
Konstantinov, S.; Georgieva, M.C.; Topashka-Ancheva, M.; Eibl, H.; Berger, M. Combination with antisense oligonucleotide synergistically improves the antileukemic efficacy of Erucylphospho-N, N, N-trimethylammonium in chronic myeloid leukemia cell lines. Mol. Cancer Ther., 2002, 1, 877-884.
[138]
Zaharieva, M.M.; Konstantinov, S.M.; Berger, M.R. The antineoplastic activity of erufosine in a panel of leukemia and lymphoma cell lines is related to selected signal proteins. Int. J. Curr. Chem., 2010, 1(4), 249-257.
[139]
Browaeys-Poly, E.; Perdereau, D.; Lescuyer, A.; Burnol, A.F.; Cailliau, K. Akt interaction with PLC(gamma) regulates the G(2)/M transition triggered by FGF receptors from MDA-MB-231 breast cancer cells. Anticancer Res., 2009, 29(12), 4965-4969.
[140]
Yosifov, D.Y.; Dineva, I.K.; Zaharieva, M.M.; Konstantinov, S.M.; Berger, M.R. The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N, N, N-trimethylpropylammonium (ErPC3). Cancer Biol. Ther., 2007, 6(6), 930-935.
[141]
Ansari, S.S.; Sharma, A.K.; Zepp, M.; Ivanova, E.; Bergmann, F.; König, R.; Berger, M.R. Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine’s down regulation of cell cycle processes in OSCC cells. Oncotarget, 2018, 9(5), 5797-5810.
[142]
Fleer, E.A.; Berkovic, D.; Grunwald, U.; Hiddemann, W. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB. Eur. J. Cancer, 1996, 32A(3), 506-511.
[143]
Muschiol, C.; Berger, M.R.; Schuler, B.; Scherf, H.R.; Garzon, F.T.; Zeller, W.J.; Unger, C.; Eibl, H.J.; Schmahl, D. Alkyl phosphocholines: Toxicity and anticancer properties. Lipids, 1987, 22(11), 930-934.
[144]
Zaharieva, M.M.; Petkov, N.; Konstantinov, S.M.; Berger, M.R. The New Alkylphosphocholine Erufosine Ameliorates Bone Marrow Toxicity of Classical Cytostatics.In Resources of Danubian Region: The Possibility of Cooperation and Utilization; Popović, L.Č.; Vidaković, M.; Kostić, D.S., Eds.; Humboldt-Club Serbien: Belgrade, 2013, pp. 376-388.
[145]
Berkovic, D.; Bensch, M.; Bertram, J.; Wille, T.; Haase, D.; Binder, C.; Fleer, E.A. Effects of hexadecylphosphocholine on thrombocytopoiesis. Eur. J. Cancer, 2001, 37(4), 503-511.
[146]
Berkovic, D.; Luders, S.; Goeckenjan, M.; Hiddemann, W.; Fleer, E.A. Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine. Biochem. Pharmacol., 1997, 53(11), 1725-1733.
[147]
Kaufmann-Kolle, P.; Drevs, J.; Berger, M.; Koetting, J.; Marschner, N.W.; Unger, C.; Eibl, H. Pharmacocinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother. Pharmacol., 1994, 34, 393.
[148]
Hilgard, P.; Klenner, T.; Stekar, J.; Nossner, G.; Kutscher, B.; Engel, J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur. J. Cancer, 1997, 33(3), 442-446.
[149]
Planting, A.S.; Stoter, G.; Verweij, J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur. J. Cancer, 1993, 29A(4), 518-519.
[150]
Verweij, J.; Krzemieniecki, K.; Kok, T.; Poveda, A.; van Pottelsberghe, C.; van Glabbeke, M.; Mouridsen, H. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC soft tissue and bone sarcoma group study. Eur. J. Cancer, 1993, 29A(2), 208-209.
[151]
Verweij, J.; Gandia, D.; Planting, A.S.; Stoter, G.; Armand, J.P. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur. J. Cancer, 1993, 29A(5), 778-779.
[152]
Unger, C.; Damenz, W.; Fleer, E.A.; Kim, D.J.; Breiser, A.; Hilgard, P.; Engel, J.; Nagel, G.; Eibl, H. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol., 1989, 28(2), 213-217.
[153]
Kaminsky, R. Miltefosine Zentaris. Curr. Opin. Investig. Drugs, 2002, 3(4), 550-554.
[154]
Dorlo, T.P.; Huitema, A.D.; Beijnen, J.H.; de Vries, P.J. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob. Agents Chemother., 2012, 56(7), 3864-3872.
[156]
Dorlo, T.P.; van Thiel, P.P.; Huitema, A.D.; Keizer, R.J.; de Vries, H.J.; Beijnen, J.H.; de Vries, P.J. Pharmacokinetics of miltefosine in old world cutaneous leishmaniasis patients. Antimicrob. Agents Chemother., 2008, 52(8), 2855-2860.
[157]
Knebel, N.G.; Grieb, S.; Winkler, M.; Locher, M.; van der Vlis, E.; Verheij, E.R. Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl., 1999, 721(2), 257-269.
[158]
Crul, M.; Rosing, H.; de Klerk, G.J.; Dubbelman, R.; Traiser, M.; Reichert, S.; Knebel, N.G.; Schellens, J.H.; Beijnen, J.H.; Huinink, B.W.W. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer, 2002, 38(12), 1615-1621.
[159]
Van Ummersen, L.; Binger, K.; Volkman, J.; Marnocha, R.; Tutsch, K.; Kolesar, J.; Arzoomanian, R.; Alberti, D.; Wilding, G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res., 2004, 10(22), 7450-7456.
[160]
Ernst, D.S.; Eisenhauer, E.; Wainman, N.; Davis, M.; Lohmann, R.; Baetz, T.; Belanger, K.; Smylie, M. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest. New Drugs, 2005, 23(6), 569-575.
[161]
Posadas, E.M.; Gulley, J.; Arlen, P.M.; Trout, A.; Parnes, H.L.; Wright, J.; Lee, M.J.; Chung, E.J.; Trepel, J.B.; Sparreboom, A.; Chen, C.; Jones, E.; Steinberg, S.M.; Daniels, A.; Figg, W.D.; Dahut, W.L. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol. Ther., 2005, 4(10), 1133-1137.
[162]
Jakubowiak, A.J.; Richardson, P.G.; Zimmerman, T.; Alsina, M.; Kaufman, J.L.; Kandarpa, M.; Kraftson, S.; Ross, C.W.; Harvey, C.; Hideshima, T.; Sportelli, P.; Poradosu, E.; Gardner, L.; Giusti, K.; Anderson, K.C. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: A phase I multiple myeloma research consortium study. Br. J. Haematol., 2012, 158(4), 472-480.
[163]
Marschner, N.W.; Koetting, J.; Eibl, H.; Unger, C. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother. Pharmacol., 1995, 31(18), 18-22.
[164]
Menez, C.; Buyse, M.; Dugave, C.; Farinotti, R.; Barratt, G. Intestinal absorption of miltefosine: contribution of passive paracellular transport. Pharm. Res., 2007, 24(3), 546-554.
[165]
Menez, C.; Buyse, M.; Farinotti, R.; Barratt, G. Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process. Lipids, 2007, 42(3), 229-240.
[166]
Menez, C.; Buyse, M.; Chacun, H.; Farinotti, R.; Barratt, G. Modulation of intestinal barrier properties by miltefosine. Biochem. Pharmacol., 2006, 71(4), 486-496.
[167]
Unger, C.; Eibl, H.; Breiser, A.; von Heyden, H.W.; Engel, J.; Hilgard, P.; Sindermann, H.; Peukert, M.; Nagel, G.A. Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial. Onkologie, 1988, 11(6), 295-296.
[168]
Terwogt, J.M.; Mandjes, I.A.; Sindermann, H.; Beijnen, J.H.; Huinink, B.W.W. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. Br. J. Cancer, 1999, 79(7-8), 1158-1161.
[169]
Smorenburg, C.H.; Seynaeve, C.; Bontenbal, M.; Planting, A.S.; Sindermann, H.; Verweij, J. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs, 2000, 11(10), 825-828.
[170]
Dumontet, C.; Thomas, L.; Berard, F.; Gimonet, J.F.; Coiffier, B. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma. Bull. Cancer, 2006, 93(11), E115-E118.
[171]
Lindner, L.H.; Eibl, H.; Hossann, M.; Vogeser, M. Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography-tandem mass spectrometry using a deuterated internal standard. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 869(1-2), 16-19.
[172]
Sindermann, H.; Engel, J. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 2006, 100(Suppl. 1), S17-S20.
[173]
Dorlo, T.P.; Balasegaram, M.; Beijnen, J.H.; de Vries, P.J. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J. Antimicrob. Chemother., 2012, 67(11), 2576-2597.
[174]
Drings, P.; Günther, I.; Gatzemeier, U.; Ulbrich, F.; Khanavkar, B.; Schreml, W.; Lorenz, J.; Brugger, W.; Schick, H.D.; Pawel, J.V.; Nordström, R. Final evaluation of a phase ii study on the effect of edelfosine (an ether lipid) in advanced non-small-cell bronchogenic carcinoma. Onkologie, 1992, 15(5), 375-382.
[175]
Vogler, W.R.; Berdel, W.E.; Geller, R.B.; Brochstein, J.A.; Beveridge, R.A.; Dalton, W.S.; Miller, K.B.; Lazarus, H.M. A phase II trial of Autologous Bone Marrow Transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Adv. Exp. Med. Biol., 1996, 416, 389-396.
[176]
Herrmann, D.B.; Neumann, H.A.; Berdel, W.E.; Heim, M.E.; Fromm, M.; Boerner, D.; Bicker, U. Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients. Lipids, 1987, 22(11), 962-966.
[177]
von Mehren, M.; Giantonio, B.J.; McAleer, C.; Schilder, R.; McPhillips, J.; O’Dwyer, P.J. Phase I trial of ilmofosine as a 24hour infusion weekly. Inv. N. Drugs, 1995, 13(3), 205-210.
[178]
Giantonio, B.J.; Derry, C.; McAleer, C.; McPhillips, J.J.; O’Dwyer, P.J. Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors. Clin. Cancer Res., 2004, 10(4), 1282-1288.
[179]
Winkelmann, M.; Ebeling, K.; Strohmeyer, G.; Hottenrott, G.; Mechl, Z.; Berges, W.; Scholten, T.; Westerhausen, M.; Schlimok, G.; Sterz, R. Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. J. Cancer Res. Clin. Oncol., 1992, 118(6), 405-407.
[180]
Dorlo, T.P.; Balasegaram, M.; Lima, M.A.; de Vries, P.J.; Beijnen, J.H.; Huitema, A.D. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. J. Antimicrob. Chemother., 2012, 67(8), 1996-2004.
[181]
Altomare, D.A.; Testa, J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene, 2005, 24(50), 7455-7464.
[182]
Ghobrial, I.M.; Roccaro, A.; Hong, F.; Weller, E.; Rubin, N.; Leduc, R.; Rourke, M.; Chuma, S.; Sacco, A.; Jia, X.; Azab, F.; Azab, A.K.; Rodig, S.; Warren, D.; Harris, B.; Varticovski, L.; Sportelli, P.; Leleu, X.; Anderson, K.C.; Richardson, P.G. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom’s macroglobulinemia. Clin. Cancer Res., 2010, 16(3), 1033-1041.
[183]
Keane, N.A.; Glavey, S.V.; Krawczyk, J.; O’Dwyer, M. AKT as a therapeutic target in multiple myeloma. Expert Opin. Ther. Targets, 2014, 18(8), 897-915.
[184]
Danielsen, S.A.; Eide, P.W.; Nesbakken, A.; Guren, T.; Leithe, E.; Lothe, R.A. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim. Biophys. Acta, 2015, 1855(1), 104-121.
[185]
Leonard, R.; Hardy, J.; van Tienhoven, G.; Houston, S.; Simmonds, P.; David, M.; Mansi, J. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J. Clin. Oncol., 2001, 19(21), 4150-4159.
[186]
Dummer, R.; Krasovec, M.; Roeger, J.; Sindermann, H.; Burg, G. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: Results of a phase I/II study. J. Am. Acad. Dermatol., 1993, 29, 963-970.
[187]
Dummer, R.; Roger, J.; Vogt, T.; Becker, J.; Hefner, H.; Sindermann, H.; Burg, G. Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas. Prog. Exp. Tumor Res., 1992, 34, 160-169.
[188]
Theischen, M.; Bornfeld, N.; Becher, R.; Kellner, U.; Wessing, A. Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium. Ger. J. Ophthalmol., 1993, 2(2), 113-115.
[189]
Pronk, L.C.; Planting, A.S.; Oosterom, R.; Drogendijk, T.E.; Stoter, G.; Verweij, J. Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. Eur. J. Cancer, 1994, 30A(7), 1019-1022.
[190]
Figg, W.D.; Monga, M.; Headlee, D.; Shah, A.; Chau, C.H.; Peer, C.; Messman, R.; Elsayed, Y.A.; Murgo, A.J.; Melillo, G.; Ryan, Q.C.; Kalnitskiy, M.; Senderowicz, A.M.; Hollingshead, M.; Arbuck, S.G.; Sausville, E.A. A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. Cancer Chemother. Pharmacol., 2014, 74(5), 955-967.
[191]
Vink, S.R.; Schellens, J.H.; Beijnen, J.H.; Sindermann, H.; Engel, J.; Dubbelman, R.; Moppi, G.; Hillebrand, M.J.; Bartelink, H.; Verheij, M. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother. Oncol., 2006, 80(2), 207-213.
[192]
Richardson, P.G.; Wolf, J.; Jakubowiak, A.; Zonder, J.; Lonial, S.; Irwin, D.; Densmore, J.; Krishnan, A.; Raje, N.; Bar, M.; Martin, T.; Schlossman, R.; Ghobrial, I.M.; Munshi, N.; Laubach, J.; Allerton, J.; Hideshima, T.; Colson, K.; Poradosu, E.; Gardner, L.; Sportelli, P.; Anderson, K.C. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase I/II trial. J. Clin. Oncol., 2011, 29(32), 4243-4249.
[193]
Fu, S.; Hennessy, B.T.; Ng, C.S.; Ju, Z.; Coombes, K.R.; Wolf, J.K.; Sood, A.K.; Levenback, C.F.; Coleman, R.L.; Kavanagh, J.J.; Gershenson, D.M.; Markman, M.; Dice, K.; Howard, A.; Li, J.; Li, Y.; Stemke-Hale, K.; Dyer, M.; Atkinson, E.; Jackson, E.; Kundra, V.; Kurzrock, R.; Bast, R.C., Jr; Mills, G.B. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol. Oncol., 2012, 126(1), 47-53.
[194]
Kaley, T.J.; Pentsova, E.; Omuro, A.M.; Mellinghoff, I.K.; Nolan, C.; Gavrilovic, I.T.; DeAngelis, L.M.; Lacouture, M.E.; Holland, E.C.; Lassman, A.B. Phase I trial of Temsirolimus (TEM) and Perifosine
(PER) for recurrent or progressive Malignant Glioma (MG). J. Clin. Oncol.,, 2013, 31, abstr 2095.
[195]
Gojo, I.; Perl, A.; Luger, S.; Baer, M.R.; Norsworthy, K.J.; Bauer, K.S.; Tidwell, M.; Fleckinger, S.; Carroll, M.; Sausville, E.A. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Inv. N. Drugs, 2013, 31(5), 1217-1227.
[196]
Knowling, M.; Blackstein, M.; Tozer, R.; Bramwell, V.; Dancey, J.; Dore, N.; Matthews, S.; Eisenhauer, E. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Inv. N. Drugs, 2006, 24(5), 435-439.
[197]
Bailey, H.H.; Mahoney, M.R.; Ettinger, D.S.; Maples, W.J.; Fracasso, P.M.; Traynor, A.M.; Erlichman, C.; Okuno, S.H. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer, 2006, 107(10), 2462-2467.
[198]
Argiris, A.; Cohen, E.; Karrison, T.; Esparaz, B.; Mauer, A.; Ansari, R.; Wong, S.; Lu, Y.; Pins, M.; Dancey, J.; Vokes, E. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol. Ther., 2006, 5(7), 766-770.
[199]
Chee, K.G.; Longmate, J.; Quinn, D.I.; Chatta, G.; Pinski, J.; Twardowski, P.; Pan, C.X.; Cambio, A.; Evans, C.P.; Gandara, D.R.; Lara, P.N., Jr The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial. Clin. Genitourin. Cancer, 2007, 5(7), 433-437.
[200]
Marsh-Rde, W.; Lima, R.C.M.; Levy, D.E.; Mitchell, E.P.; Rowland, K.M., Jr; Benson, A.B., III A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am. J. Clin. Oncol., 2007, 30(1), 26-31.
[201]
Leighl, N.B.; Dent, S.; Clemons, M.; Vandenberg, T.A.; Tozer, R.; Warr, D.G.; Crump, R.M.; Hedley, D.; Pond, G.R.; Dancey, J.E.; Moore, M.J. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res. Treat., 2008, 108(1), 87-92.
[202]
Friedman, D.R.; Lanasa, M.C.; Davis, P.H.; Allgood, S.D.; Matta, K.M.; Brander, D.M.; Chen, Y.; Davis, E.D.; Volkheimer, A.D.; Moore, J.O.; Gockerman, J.P.; Sportelli, P.; Weinberg, J.B. Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies. Leuk. Lymphoma, 2014, 55(5), 1067-1075.
[203]
Cho, D.C.; Hutson, T.E.; Samlowski, W.; Sportelli, P.; Somer, B.; Richards, P.; Sosman, J.A.; Puzanov, I.; Michaelson, M.D.; Flaherty, K.T.; Figlin, R.A.; Vogelzang, N.J. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer, 2012, 118(24), 6055-6062.
[204]
Guidetti, A.; Carlo-Stella, C.; Locatelli, S.L.; Malorni, W.; Mortarini, R.; Viviani, S.; Russo, D.; Marchiano, A.; Sorasio, R.; Dodero, A.; Farina, L.; Giordano, L.; Di Nicola, M.; Anichini, A.; Corradini, P.; Gianni, A.M. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. Clin. Cancer Res., 2014, 20(22), 5641-5651.
[205]
Becher, O.J.; Gilheeney, S.W.; Khakoo, Y.; Lyden, D.C.; Haque, S.; De Braganca, K.C.; Kolesar, J.M.; Huse, J.T.; Modak, S.; Wexler, L.H.; Kramer, K.; Spasojevic, I.; Dunkel, I.J. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatr. Blood Cancer, 2017, 64(7)
[206]
Bendell, J.C.; Ervin, T.; Senzer, N.; Richards, D.A.; Firdaus, I.; Lockhart, C.; Cohn, A.; Saleh, M.; Gardner, L.; Sportelli, P.; Eng, C. Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). Clin. Oncol., 2012, 30
[207]
Richardson, P.G.; Nagler, A.; Ben-Yehuda, D.; Badros, A.; Hari, P.; Hajek, R.; Spicka, I.; Kaya, H.; Le Blanc, R.; Yoon, S-S.; Kim, K.; Martinez-Lopez, J.; Mittelman, M.; Shpilberg, O.; Tothova, E.; Laubach, J.P.; Ghobrial, I.M.; Leiba, M.; Gatt, M.E.; Sportell, P.; Chen, M.; Anderson, K.C. In Randomized placebo-controlled
phase III study of perifosine combined with bortezomib and dexamethasone
in relapsed, refractory multiple myeloma patients previously
treated with bortezomib, 55 th ASH Annual Meeting and
Exposition. 2013, p 3189.
[208]
Shome, D.; Trent, J.; Espandar, L.; Hatef, E.; Araujo, D.M.; Song, C.D.; Kim, S.K.; Esmaeli, B. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. Ophthalmology, 2008, 115(3), 483-487.
[209]
Keenan, J.D.; Fram, N.R.; McLeod, S.D.; Strauss, E.C.; Margolis, T.P. Perifosine-related rapidly progressive corneal ring infiltrate. Cornea, 2010, 29(5), 583-585.
[210]
Grudzinski, J.J.; Titz, B.; Kozak, K.; Clarke, W.; Allen, E.; Trembath, L.; Stabin, M.; Marshall, J.; Cho, S.Y.; Wong, T.Z.; Mortimer, J.; Weichert, J.P. A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. PLoS One, 2014, 9(11), e111652.
[211]
Lubner, S.J.; Mullvain, J.; Perlman, S.; Pishvaian, M.; Mortimer, J.; Oliver, K.; Heideman, J.; Hall, L.; Weichert, J.; Liu, G. A phase 1, multi-center, open-label, dose-escalation study of 131I-CLR1404 in subjects with relapsed or refractory advanced solid malignancies. Cancer Invest., 2015, 33(10), 483-489.
[213]
Sundar, S.; Rosenkaimer, F.; Makharia, M.K.; Goyal, A.K.; Mandal, A.K.; Voss, A.; Hilgard, P.; Murray, H.W. Trial of oral miltefosine for visceral leishmaniasis. Lancet, 1998, 352(9143), 1821-1823.
[214]
Jha, T.K.; Sundar, S.; Thakur, C.P.; Bachmann, P.; Karbwang, J.; Fischer, C.; Voss, A.; Berman, J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med., 1999, 341(24), 1795-1800.
[215]
Sundar, S.; Gupta, L.B.; Makharia, M.K.; Singh, M.K.; Voss, A.; Rosenkaimer, F.; Engel, J.; Murray, H.W. Oral treatment of visceral leishmaniasis with miltefosine. Ann. Trop. Med. Parasitol., 1999, 93(6), 589-597.
[216]
Cojean, S.; Houze, S.; Haouchine, D.; Huteau, F.; Lariven, S.; Hubert, V.; Michard, F.; Bories, C.; Pratlong, F.; Le Bras, J.; Loiseau, P.M.; Matheron, S. Leishmania resistance to miltefosine associated with genetic marker. Emerg. Infect. Dis., 2012, 18(4), 704-706.
[217]
Sundar, S.; Sinha, P.K.; Rai, M.; Verma, D.K.; Nawin, K.; Alam, S.; Chakravarty, J.; Vaillant, M.; Verma, N.; Pandey, K.; Kumari, P.; Lal, C.S.; Arora, R.; Sharma, B.; Ellis, S.; Strub-Wourgaft, N.; Balasegaram, M.; Olliaro, P.; Das, P.; Modabber, F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet, 2011, 377(9764), 477-486.
[218]
Sundar, S.; Rai, M.; Chakravarty, J.; Agarwal, D.; Agrawal, N.; Vaillant, M.; Olliaro, P.; Murray, H.W. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis., 2008, 47(8), 1000-1006.
[219]
Croft, S.L.; Engel, J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans. R. Soc. Trop. Med. Hyg., 2006, 100(Suppl. 1), S4-S8.
[220]
Avlonitis, N.; Lekka, E.; Detsi, A.; Koufaki, M.; Calogeropoulou, T.; Scoulica, E.; Siapi, E.; Kyrikou, I.; Mavromoustakos, T.; Tsotinis, A.; Grdadolnik, S.G.; Makriyannis, A. Antileishmanial ring-substituted ether phospholipids. J. Med. Chem., 2003, 46(5), 755-767.
